A Genetic Study for Alzheimer Dementia: Case-control Study

Not yet recruiting

• Conditions: Alzheimer Dementia (AD)

• Registration Number: NCT06330155
• Lead Sponsor: MinYoung Kim, MD, PhD

Brief Summary

The purpose of this study is to find out the difference in genetic test results between Alzheimer's dementia patients and healthy subjects.

The investigators want to identify genes that are importantly related to Alzheimer's dementia.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-03-19
• Study First Submitted QC: 2024-03-19
• Study Start: 2024-03-26
• Study First Posted: 2024-03-26
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-02
• Last Update Posted: 2024-04-04
• Primary Completion: 2026-12-31
• Study Completion: 2026-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Alzheimer's dementia patient

• Adult patients over 60 years old
• Patients with a Alzheimer's dementia patient
• Total Korean version of mini-mental state examination (K-MMSE) score less than 24
• Total Clinical Dementia Rating (CDR) over 0.5

2. Inclusion Criteria: healthy subjects

   • Adult healthy over 60 years old
   • Total Korean version of mini-mental state examination (K-MMSE) over 24
   • Total Clinical Dementia Rating (CDR) is 0

Exclusion Criteria

• Those with severe medical conditions such as unstable conditions of the cardiovascular system, digestive system, respiratory system, endocrine system, etc., who are in poor general condition
  • In the case of a person with impaired consent (MMSE less than 10 points), if not accompanied by a guardian
  • Other cases where the researcher determines that participation in this clinical trial is not appropriate (Patients who are participating in other studies or have participated in other studies within the past 30 days can also participate in this study.)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
genetic analysis	Baseline	5cc blood collection for genetic testing

Secondary Outcome Measures

Name	Time	Method
Measurement of Korean version of mini-mental state examination (K-MMSE)	screening, Baseline	K-MMSE is a measurement of cognitive level. Any score of 24 or more (out of 30) indicates a normal cognition. Below this, scores can indicate severe(≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment(MCI). The raw score may also need to be corrected for educational attainment and age.
Measurement of Geriatric Depression Scale (GDSd)	Baseline	GDS is a 30-item self-report assessment used to identify depression in the elderly. One point is assigned to each answer and the cumulative score is rated on a scoring grid. The grid sets a range of 0-9 as "normal", "10-19" as "mildly depressed", and 20-30 as "severely depressed".
Measurement of Clinical Dementia Rating (CDR)	screening, Baseline	CDR is a rating scale for staging patients diagnosed with dementia. The CDR evaluates cognitive, behavioral and functional aspects of Alzheimer disease and other dementias. It is calculated on the basis of testing six different cognitive and behavioral domains such as memory, orientation, judgment and problem solving, community affairs, home and hobbies performance, and personal care. The CDR is based on a scale of 0-3: no dementia (CDR = 0), questionable dementia (CDR = 0.5), MCI (CDR = 1), moderate cognitive impairment (CDR = 2) and severe cognitive impairment (CDR = 3)